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Abstract
Background: The severe forms of asthma represent a major burden, because of severity of symptoms, costs and
impact on everyday life. Recently, Mepolizumab (MEP) was approved and marketed for the treatment of
hypereosinophilic severe asthma. This anti-IL-5 monoclonal antibody reduced exacerbation rates and oral
corticosteroid (OCS) use in well selected patients. The aim of this study was to evaluate the characteristics of
patients receiving MEP in a real-life setting. Thus, we describe a retrospective analysis of patients treated with MEP
in six centres in North Western Italy, including those who participated in the main regulatory trials.
Methods: The baseline data, before prescription, from six North Western Italy severe asthma clinics, between June
1st 2017 and December 31st 2017, were evaluated. The collected real-life data were then compared with those of
SIRUS, MENSA, DREAM and MUSCA trials.
Results: Sixty-five patients were included (45% female; mean age 56 years; age range 19–84). Main observed
differences with regulatory trials could be observed in eosinophils blood count at baseline, where the mean of our
real-life patients (653 cells/μL) was overall higher than the one of all trials (240 cells/μL, 296 cells/μL, 253 cells/μL; p
< 0.0001). The incidence of polyposis was also significantly higher in our sample (72% vs. 24%, 49%, 10%, 19%; p
< 0.0001). The daily average dose of OCS was lower in our real-life patients (9 mg), if compared with SIRIUS (13.
7 mg), MENSA (13.2) and MUSCA (13), and similar to the data published in DREAM (10.8).
Conclusions: The comparison of real-life patients' characteristics with regulatory trials, displayed several apparent
discrepancies. The demographic and clinical aspects were similar in all groups, whereas other features (eosinophil
count, pulmonary function FEV1%) differed. These data, for the first time, could represent a basis for a more
accurate prescription of the drug.
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Background
Asthma is a common chronic respiratory disease, which
prevalence ranges between 1 and 18%, with slight variations
among Countries, and according to selection criteria and
methodology [1]. The severe form affects about 5–10% of
asthmatic patients. According to guidelines of the Ameri-
can Thoracic Society and European Respiratory Society
(ATS/ERS) [2], a “severe” patient needs a maximal therapy
(step 4–5 GINA) [3] with the chronic use of systemic ste-
roids, usually oral corticosteroids (OCS). To provide a dif-
ferent therapeutic approach to the more severe forms of
asthma, biological treatments targeting the known patho-
genic mechanisms have been hypothesized and realized.
The first commercialized biological treatment was Omali-
zumab (an anti-IgE antibody) [4]. Recently, an IL-5 antag-
onist was commercialized, mepolizumab (MEP), directed to
circulating IL-5. Its effectiveness in hypereosinophilic
asthma is now well ascertained [5]. In clinical trials MEP
displayed a favourable efficacy in reducing exacerbations,
OCS intake, and in enhancing the quality of life (QoL). It
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appeared that a careful selection of patients is needed to
achieve the best results. In fact, in the earliest trial MEP
was given to a non-selected population of patients with
moderate persistent asthma and variable levels of eosino-
phils. No significant clinical result emerged for asthma con-
trol and specific bronchial hyperresponsiveness [6, 7].
Subsequently, other big trials including patients with at
least 150–300 eosinophils/mmc) were performed, with
favourable results [8–11]. Following the commercial release
of MEP, we attempted to strictly evaluate the characteristics
of the treated patients in a real-life setting, as compared to
regulatory trials. In this retrospective we provide a descrip-
tion of the characteristics of patients treated with MEP, in
six centres in the North-Western Italy, including those who
participated in the main clinical trials.
Methods
This is a retrospective analysis of patients from six
severe asthma clinics of North West Italy (IRCCS
Policlinico San Martino Genoa, Santa Corona Hos-
pital Pietra Ligure, AO Mauriziano, AOU Città della
Salute e della Scienza Turin, Humanitas University
Milan, and Fondazione Poliambulanza Brescia), which
were the first clinics to have the product available.
All patients meet the ATS/ERS criteria for uncon-
trolled severe asthma [2] and the conditions to be
prescribed with MEP according to the Italian Drug
Agency. A documented blood eosinophilia of at least
300 cells/mmc in the previous year, a current count
of at least 150 cells/mmc and at least 2 cycles of
OCS during the previous year, or continuous OCS
therapy [12] were required. All patients started MEP
treatment between June 1st, 2017 and December 31st,
2017, at the dose of 100 mg subcutaneously every
month. The data of the considered patients were
matched with those of SIRIUS, MENSA, DREAM and
MUSCA [8–11] studies.
All procedures described herein were performed as
per standard of care. The study was observational,
with approved and commercialized drugs. No ap-
proval from the Ethics Committees was required
according to the Italian laws. The privacy rules were
applied and all patients provided an informed consent
to be treated.
Statistical analysis
All patients receiving MEP in the aforementioned period
were included in the analysis. Arithmetic mean and standard
deviation were used for the descriptive statistics. To com-
pare data of our patients with those of the four mentioned
clinical randomised, double-blind, placebo-controlled studies
[8–11], a weighted average was used due to the difference in
sample sizes. To compare our data with those of the main
clinical trials with MEP we used a t-test one sample and a
Z-test one proportion when indicated. A p value of ≤0.05
was considered to be significant.
Results
General description
Starting from June 1st, 2017 to December 31st, 2017,
65 severe hypereosinophilic asthmatic patients were
treated. All patients were classified as step 4/5 GINA
[3], remaining uncontrolled despite the maximal ther-
apy [2]. The mean age was 56 ± 11.5 (range 19–84)
(Table 1). Seven patients (11%) had their asthma
symptoms before adolescence. Mean age of onset of
asthma was 38 ± 16.5 (range 2–68), with a mean dur-
ation of the disease, before MEP treatment of
18.2 years (±14.4). Females accounted for 45% of the
whole population. 17/65 patients (26%) were former
or current smokers.
The control of the disease was evaluated with vali-
dated asthma control test (ACT) at baseline with a
mean value of 16.6 ± 4.7 (range 6–25). Also lung
function test prior to MEP evidenced a mean forced
expiratory volume at the first second (FEV1) of 73 ±
18%. Fifty-three out of 65 patients (82.5%) were re-
ceiving daily OCS therapy at the time of inclusion,
with a mean dose of 9.2 mg (±9.2) of prednisolone
(different molecules were converted in prednisolone
equivalent). The mean eosinophils level at baseline,
before treatment, was 653 cells/mmc (range 150–1987),
with a mean historical value in the previous year of 1046
cells/mmc (range 320–6000). Nasal polyps were docu-
mented (by fiberoptic rhinoscopy and/or computerized
tomography) in 47 (72%) subjects. 7/65 (11%) patients
Table 1 The current observed population receiving MEP
SD or percentage
Number of patients 65 –
Female/Male 29/36 45% female
Age range 19–84 –
Age mean 56 ±11.5
Current smoker 17 26%
Duration of asthma (years) 18.2 ± 14.4
Historical eosinophilic count 1046 ± 885
Blood eosinophil count at
baseline
653 ±381
Mean exacerbations previous
12 months
3.0 ±1.8
Hospitalized patients previous
12 months
20 31%
Mean OCS dose at baseline (mg) 9.2 ±9.2
Mean FEV1 at baseline (%) 73 ±18.1
ACT 16.6 ±4.7
Concomitant nasal polyposis 47 72%
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come from the previous regulatory trials conducted at
our centres.
Comparison with the clinical trials (Table 2)
The mean age in our real-life sample was 56 years, with
a statistically significant difference compared to MUSCA
(51 years; p < 0.0005), DREAM (46 years; p < 0.0001),
MENSA and SIRIUS (50; p < 0.0001). Concerning gen-
der, MEP was given to 29/56 women (45%) in the
real-life sample. A statistically significant difference to-
wards the four examined trials was seen with the
DREAM study (387/621 p = 0.0033) and the MUSCA
study (325/551, 58% p = 0.04). Concerning smoking
habit, in our sample 17/65 (26%) were current or former
smokers at baseline. If in DREAM, MENSA and
MUSCA study the percentage of smoking people was
similar to which observed in our sample, the same can-
not be said about the SIRIUS study, where the percent-
age of smokers was higher (39%; p = 0.0459).
The duration of asthma was also considered, calcu-
lated as the difference between the date of first MEP ad-
ministration and the reported first occurrence of asthma
symptoms. The range spans widely from 2 to 68 years,
but only 7 patients complained of symptoms before the
age of 20 years. The average age of onset of asthma was
38 years, with a mean duration of 18.2 (±14.2) years. In
this context our data parallel those collected in the main
clinical trials. Pulmonary function was evaluated accord-
ing to Global Lung Function Initiative (GLI) predictions
[13], and the mean percentage of FEV1 was 73 ± 18.1%.
Also in this case, the observed values were different
from those of clinical trials, where the weighted averages
were 58.7 (±17.7) in SIRIUS, 61 (±17.9) in MENSA, 60
(±16.0) in DREAM and 55 (±14.5) in MUSCA, all value
with a statistically difference < 0.0001. The range of eo-
sinophils, in the previous and current years, was broadly
distributed with a mean value of 1046 (range 320–6000)
cells/μl and 653 (range 150–1987) cells/μl, respectively.
Matching these results with those of previous clinical tri-
als, a mean value of 653 (±381) cells/μl was recorded in
our cohort, whereas in the four randomized trials the
concentration of eosinophils at baseline (SIRIUS 240
cells/μl, MENSA 296 cells/μl, DREAM 253 cells/μl and
325 for MUSCA) was lower, all with a statistically sig-
nificant difference (p < 0.0001). Comparing our data
with that of the MUSCA study, where eosinophils were
Table 2 Comparison among groups. Real-life population and regulatory studies. The significant difference for the available
parameters are indicated in boldface
CURRENT POPULATION SIRIUS (11) MENSA(10) DREAM (8) MUSCA (9)
Age Mean ± SD (range) 56 ± 11.5 (19–84) 50 (n.p.) (16–74) 50 (n.p.) (12–82) 46 ± 11.2 (n.p.) 51 ± 13.4 (n.p.)
P-value – < 0.0001 < 0.0001 < 0.0001 < 0.0001
Female % N (%) 29 (45) 27 (55) 329 (57) 392 (63) 325 (58)
P-value – n.s n.s 0.003 0.039
Duration of asthma
(years)
Mean ± SD 18.2 ± 14.4 18.27 ± 13.1 19.9 ± 13.8 19.1 ± 45.8 19.5 ± 14.8
P-value – n.s. n.s n.s n.s
Smoker N (%) 17 (26) 53 (39) 159 (28) 133 (22) 147 (26)
P-value – 0.04 n.s. n.s n.s
FEV1% Mean ± SD 73 ± 18.1 58.7 ± 17.7 61 ± 17.9 60 ± 16 55 ± 14.5
P-value – < 0.0001 < 0.0001 < 0.0001 < 0.0001
Eosinophils
baseline (cells/μl)a
Mean ± SD
N (%)
653 ± 381
≥150 = 64 (98)
≥300 = 9 (91)
240 ± 1126
(n.p.)
(n.p.)
296 ± 992
(n.p.)
(n.p.)
253 ± 1022
(n.p.)
n.p.)
325 (n.p.)
≥150 = 474 (86)b
≥300 = 351 (64)b
P-value – < 0.0001 < 0.0001 < 0.0001 0.0043b
< 0.0001b
Exacerbations/
12 months
Mean ± SD 3 (1.8) 3.1 (3.1) 3.6 (2.6) 3.58 (3.03) 2.8 (1.7)
P-value – n.s. 0.0047 0.0087 n.s.
ER access/
12 months
N (%) 20 (31) 23 (17) 109 (19) 150 (24) 179 (32)
P-value – 0.005 n.s n.s n.s
OCS dose at
baseline
Median (range)
Mean (SD)
9 (0–50)
9.2 ± 9.2
13.7 (5–35)
(n.p.)
13.2 (1–80)
(n.p.)
10.8 (8–20)
(n.p.)
(n.p.)
13 (±10.9)
P-value – 0.0002 0.0007 n.s. 0.0014
Nasal polyposis N (%) 47 (72) 33 (24) 281 (49) 62 (10) 105 (19)
P-value – < 0.0001 < 0.0001 < 0.0001 < 0.0001
aGeometric mean, n.p not provided, bcomparison in % of patients, n.s not significant
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categorized in two ranges, we observed a statistically sig-
nificant difference in both groups (98% vs 86%, p =
0.0043 in ≥150 cells/μL; 91% vs. 64%, p < 0.0001 in ≥300
cells/μL). The mean exacerbation rate of our population
was 3.0 (±1.8), not different from of SIRIUS (±3.1; p =
0.5644), MUSCA (±1.7; p = 0.4561), and lower than in
MENSA (3.6 ± 2.6; p = 0.0047) and DREAM (3.58 ± 3.03;
p = 0.0087). The percentage of subjects hospitalized or
requiring emergency room visit, was higher in our sam-
ple (31%) as compared to SIRIUS (17%; p = 0.005) and
MENSA (19%; p = 0.024), similar in MUSCA (32%; p =
0.94) and lower in the DREAM trial (24%; p = 0.26).
The use of OCS is a main determinant in severe asthma.
Among our real-life patients, 53 had a daily prescription of
OCS (5–50 mg of prednisone or equivalent, mean value
9.2 mg). Only in the DREAM study the daily dose was simi-
lar to our patients, (10.76 mg; p = 0.1715), in SIRIUS
(13.7 mg; p = 0.0002), MENSA (13.2 mg; p = 0.0007) and
MUSCA (13 mg; p = 0.0014) trials. The daily dose was on
average higher than in our sample. Finally, ACT was some-
where used to evaluate the QoL, but this aspect was diffi-
cult to compare, since different instruments were used in
the different studies. When the presence of nasal polyps
was assessed by endoscopy [14], in the real-life population
the percentage of patients with nasal polyps was surpris-
ingly highest than in the reference trials: 72% in real life,
49% in MENSA (p = 0.0003), 19% in MUSCA (p < 0.0001)
and 10% in DREAM (p < 0.0001). No data were available
from the SIRIUS study. This may be explained by the strict
inclusion criteria of the regulatory trials that were not ap-
plied to our real-life patients. Also, it has to be considered
that the association of polyposis, asthma and hypereosino-
phia is quite frequent, and usually underdiagnosed [15].
Discussion
Our clinics began to use MEP in the real-life setting, since
the drug was approved and released by the local regula-
tory agency. Thus, we attempted to evaluate the character-
istics of eligible patients, and to compare the data to those
obtained from the major regulatory-oriented trials. The
data herein collected in real-life setting confirm that eo-
sinophilic asthma is predominantly a disease of adulthood
(late onset asthma) [16], as compared with the early onset
form that is most frequently characterized by an
allergic-mediated pattern. At variance with omalizumab,
where FEV1 below 80% of predicted was mandatory to
start the add-on treatment in severe uncontrolled asthma
[17], no limitation in lung function was recommended to
prescribe MEP [18].
With the commercialization of MEP severe uncontrolled
hypereosinophilic asthma certainly achieved more expanded
therapeutic improvement. The clinical data about efficacy
(reduction of exacerbations, decrease in OCS use, improved
QoL) together with the safety profile are promising. It is true
that, in comparison with the regulatory trials, in real life, the
high level of blood eosinophils count is essential to decide
for the IL-5 antagonism strategy. The possibility of decreas-
ing the OCS burden would be regarded as a relevant
socio-economical advantage [19].
Nevertheless, this observational trial evidenced some
discrepancies between real life patients and clinical trials.
The age at first administration and gender are probably
not relevant, whereas the presence of eosinophils blood
count at baseline or the presence of nasal polyposis are
of importance. Also, it seems from the real-life observa-
tion that a more precise judgement would require at
least 1 year of treatment.
One of the main endpoints of all biological drugs remains,
in severe asthma, the reduction of the use of OCS or inhaled
corticosteroids [19] and in this context, the use of MEP pro-
duced a significant reduction in OCS usage. Although ran-
domized controlled trials (RTCs) play a pivotal role in the
experimental development plan of a drug [20–23], and its
subsequent clinical use, often the characteristics of the pa-
tients enrolled in the registration clinical trials do not reflect
what happens in real-life.
Conclusions
We report herein the characteristics of a real-life patient
population compared to the “formal” trials, showing some
apparent discrepancies among the populations. In general,
the demographic and clinical aspects were similar among
the patient groups, but the groups themselves displayed
some differences that could be taken into account for a
more refined definition of the appropriate prescription.
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